SCHEMBL2839359

SCHEMBL2839359

Cc1ccc(C(NC(=O)OC(C)(C)C)C(=O)O)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 1/20 0.44
CTSS P25774 2/20 0.43
CTSK P43235 2/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
LMNA P02545 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
GABRB1 P18505 1/20 0.41
GABRB2 P47870 1/20 0.41
FOLH1 Q04609 1/20 0.41
ALDH1A1 P00352 5/20 0.40
TP53 P04637 1/20 0.40
TRPA1 O75762 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.39
ACE P12821 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30371015 0.90 S1PR3 (0.46) S1PR3CTSSCTSKAKR1C3AKR1C2
SCHEMBL20588318 0.90 S1PR3 (0.46) S1PR3CTSSCTSKAKR1C3AKR1C2
SCHEMBL14551912 0.89 S1PR3 (0.47) S1PR3CTSSCTSKGABRB1GABRB2
SCHEMBL11389367 0.87 FOLH1 (0.54) S1PR3CTSSCTSKGABRB1GABRB2
SCHEMBL30468515 0.86 S1PR3 (0.48) S1PR3CTSSCTSKGABRB1GABRB2
SCHEMBL2835000 0.86 S1PR3 (0.48) S1PR3CTSSCTSKGABRB1GABRB2
SCHEMBL23414076 0.85 CTSS (0.44) S1PR3CTSSCTSKGABRB1GABRB2
SCHEMBL2836606 0.85 S1PR3 (0.42) S1PR3CTSSCTSKAKR1C3AKR1C2
SCHEMBL3375654 0.85 AAK1 (0.46) S1PR3CTSSCTSKLMNAKMT2A
SCHEMBL2834723 0.84 S1PR3 (0.45) S1PR3CTSSCTSKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CTSS 3935/4885CTSK 4555/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CTSS 3935/4885CTSK 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.